DaVita Inc. filings document the operating results, governance and capital structure of a public kidney care and dialysis services company. Its 8-K reports furnish quarterly financial results, including revenue, operating income, per-share results, cash flow measures, treatment economics and share repurchase activity.
Proxy filings cover board matters, executive compensation, shareholder voting items and governance disclosures. Other current reports record material financing arrangements, amendments to secured credit facilities, share repurchase authorizations and the company's common stock listing on the New York Stock Exchange under DVA.
ACKERMAN JOEL reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. insider filing shows equity awards to its CFO. Joel Ackerman, CFO and Treasurer of DaVita Inc., received two grants of common stock, covering 6,585 and 65,997 shares at no cost, as part of performance stock unit awards. These shares relate to performance stock units granted on March 15, 2022 and March 15, 2023, of which 100% will vest on March 15, 2026. Following these awards, he directly holds 221,019 shares of DaVita common stock.
DaVita Inc. Chief Legal & Public Affairs Officer Kathleen Alyce Waters reported two stock awards of common shares. On March 10, 2026, she acquired 4,829 shares of DaVita common stock at a price of $0.00 per share and separately acquired 51,330 additional shares, also at $0.00 per share.
Footnotes explain these shares were received upon satisfaction of criteria for performance stock units granted on March 15, 2022 and March 15, 2023, with 100% of each award scheduled to vest on March 15, 2026. Following these acquisitions, Waters directly holds 155,277 shares of DaVita common stock.
DaVita Inc. reported 2025 consolidated revenue of $13.643 billion, up 6.5% from 2024, while net income was $1.079 billion, down 13.7%. Net cash provided by operating activities was $1.887 billion, down 6.7%, and operating income was $2.044 billion, down 2.2%. U.S. dialysis revenue rose 3.5% to $11.793 billion; patient-service revenue per treatment increased 4.7% to $409.56, while treatments fell 1.1% to 28,733,980. DaVita attributed lower treatment volume primarily to higher mortality, missed treatments during a more severe flu season and fewer treatment days.
Ancillary-services revenue rose 27.3% to $1.922 billion, primarily reflecting international operations; international revenue increased 37.8%. DaVita repurchased 12,678,623 shares for aggregate consideration of $1.788 billion in 2025 and reported a 14.9% net reduction in outstanding share count year over year. The second-quarter cybersecurity incident led to approximately $1.0 million in patient-care charges and approximately $24.2 million in general and administrative expense; these costs exclude business-interruption effects. For 2026, DaVita expects approximately flat U.S. dialysis treatment volumes and operating income growth in its U.S. dialysis, international and integrated kidney care businesses.
DaVita Inc.’s Chief Legal & Public Affairs Officer, Kathleen Alyce Waters, reported several transactions on February 6, 2026. She exercised 8,079 Stock Appreciation Rights at an exercise price of $108.93, receiving the same number of common shares.
On the same date, she disposed of 5,898 shares of common stock at $149.22, and 817 shares were withheld to cover tax obligations related to the Stock Appreciation Rights exercise. After these transactions, she directly owned 99,118 shares of DaVita common stock.
DaVita Inc. CFO Joel Ackerman reported multiple equity transactions on February 6, 2026. He exercised 44,065 Stock Appreciation Rights at an exercise price of $108.93, receiving the same number of DaVita common shares. He then sold 32,168 common shares at $149.22 and had 5,100 shares withheld to cover tax obligations tied to the option exercise. After these transactions, he directly owned 148,437 DaVita common shares.
DaVita Inc. reported a large shareholder transaction involving entities affiliated with Berkshire Hathaway Inc. and Warren E. Buffett. On January 29, 2026, they reported the sale of 1,658,480 shares of DaVita common stock at $120.5561 per share, reported as indirectly owned.
After this sale, they reported indirect beneficial ownership of 30,100,585 DaVita shares. Of this total, 15,126,977 shares are owned by Government Employees Insurance Company, a Berkshire subsidiary. Another 14,973,608 shares are held by pension plans of Berkshire subsidiaries. Berkshire and Mr. Buffett may be deemed beneficial owners but expressly disclaim beneficial ownership except to the extent of any pecuniary interest.
DaVita Inc. filed a current report to announce that it has issued a press release with its financial results for the quarter ended December 31, 2025. The company furnished this earnings release as an exhibit rather than filing it, which limits how it is treated under securities laws.
The report identifies the press release as Exhibit 99.1 and confirms that DaVita’s common stock continues to trade on the New York Stock Exchange under the symbol DVA.
DaVita Inc. reported an insider equity transaction by its Chief Compliance Officer. On 12/04/2025, the officer exercised stock appreciation rights covering 5,875 shares of DaVita common stock at a base price of $108.93 per share, receiving shares instead of cash. On the same date, 5,412 shares of common stock were disposed of at $118.25 per share, and an additional 203 shares were withheld at $118.25 per share to cover tax obligations related to the exercise.
After these transactions, the officer beneficially owned 26,298 shares of DaVita common stock in direct form. The stock appreciation rights used in this exercise were originally granted on March 15, 2021 and vested in two equal installments on March 15, 2024 and March 15, 2025.
DaVita Inc. entered into an Eighth Amendment to its existing Credit Agreement, adding a new five-year secured term loan A facility of up to $2 billion and a new five-year secured revolving credit facility of up to $1.5 billion. These new facilities are designed to refinance amounts outstanding under the company’s prior term loan A and revolving credit facilities that were scheduled to mature in April 2028.
Borrowings can be made in U.S. dollars, euros, or pounds sterling, with interest based on benchmark rates such as Term SOFR, EURIBOR, or Daily Simple SONIA plus an Applicable Margin. The initial margin is 150 basis points for benchmark-based loans and 50 basis points for Base Rate loans, with both the margin and the undrawn commitment fee later tied to a leverage ratio grid after financial statements for the quarter ending March 31, 2026 are delivered. The new term loan amortizes quarterly starting March 31, 2026, and proceeds are allocated to repay the prior facilities, pay related fees and expenses, and support working capital and general corporate purposes, including potential stock repurchases, acquisitions, and investments.
DaVita Inc. (DVA) director reports stock acquisition. A director of DaVita Inc. reported acquiring 411 shares of the company’s common stock on 11/15/2025 in a transaction priced at $0 per share, as disclosed on a Form 4. Following this transaction, the director beneficially owns 13,981 shares of DaVita common stock, held directly.